Targeting the androgen receptor pathway in prostate cancer.

[1]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[2]  D. Tindall,et al.  Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer , 2008 .

[3]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[5]  E. Appella,et al.  Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth , 2007, Oncogene.

[6]  M. Ittmann,et al.  Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. , 2007, The Journal of urology.

[7]  F. D. De Braud,et al.  Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity , 2007, Anti-cancer drugs.

[8]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[9]  M. Gross,et al.  A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer , 2007, BMC cancer.

[10]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[11]  J. Mohler,et al.  Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation , 2007, Proceedings of the National Academy of Sciences.

[12]  P. Kantoff,et al.  Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study , 2007, Clinical Cancer Research.

[13]  David S Mendelson,et al.  Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Cloughesy,et al.  PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors , 2007, Clinical Cancer Research.

[15]  H. Scher,et al.  Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation , 2007, Molecular Cancer Therapeutics.

[16]  M. Morris,et al.  Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials , 2006, Nature Clinical Practice Oncology.

[17]  T. Vomastek,et al.  Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. , 2006, Cancer research.

[18]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[19]  W. Gerald,et al.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer , 2006, Proceedings of the National Academy of Sciences.

[20]  M. Shen,et al.  Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. , 2006, Cancer research.

[21]  Tao Zhang,et al.  Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. , 2006, The American journal of pathology.

[22]  J. Isaacs,et al.  Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.

[23]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[24]  C. Glass,et al.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. , 2006, Genes & development.

[25]  Neal Rosen,et al.  Hsp90: a novel target for cancer therapy. , 2006, Current topics in medicinal chemistry.

[26]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[27]  S. Slovin.  Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing? , 2006, Nature Clinical Practice Urology.

[28]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[29]  Karl G. Kohlgraf,et al.  Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor–Positive Prostate Cancer Cells , 2006, Molecular Cancer Research.

[30]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[32]  P. Atadja,et al.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 , 2005, Molecular Cancer Therapeutics.

[33]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[34]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[35]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[36]  C. G. Korkmaz,et al.  Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. , 2004, The Journal of endocrinology.

[37]  W. Gerald,et al.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.

[38]  E. Crawford,et al.  The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.

[39]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[41]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[42]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Fujita,et al.  The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor , 2004, Cancer Research.

[45]  K. Grigor,et al.  Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.

[46]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. McPhaul.  Androgen receptor mutations and androgen insensitivity , 2002, Molecular and Cellular Endocrinology.

[48]  S. Yeh,et al.  Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Scher,et al.  Outcome predictions for patients with metastatic prostate cancer. , 2002, Seminars in urologic oncology.

[50]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[52]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[53]  B. Katzenellenbogen,et al.  Nongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors Dissociation from Transcriptional Activity , 2001, Cell.

[54]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[55]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[56]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[57]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[58]  L. Schwartz,et al.  Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease , 1998 .

[59]  B. Haynes,et al.  Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase) , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[60]  H. Scher,et al.  Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.

[61]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[62]  D. Tindall,et al.  Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. , 2008, European urology.

[63]  Zhiyong Guo,et al.  Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation (DOI:10.1016/j.ccr.2006.08.021) , 2007 .

[64]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[65]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[66]  E. Latulippe,et al.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.

[67]  P. Gumerlock,et al.  Molecular biology of prostate cancer , 2004, World Journal of Urology.

[68]  L. Collette,et al.  Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Holger Moch,et al.  Advances in Brief Survey of Gene Amplifications during Prostate Cancer Progression by High-Throughput Fluorescence in Situ Hybridization on Tissue Microarrays 1 , 1999 .

[70]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.

[71]  M. Dowsett,et al.  Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). , 1994, The Journal of steroid biochemistry and molecular biology.